{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:19:13Z","timestamp":1790727553851,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-056399"],"award-info":[{"award-number":["INV-056399"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["OPP1066878"],"award-info":[{"award-number":["OPP1066878"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016962","name":"Department of Science and Innovation, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007112","name":"Universityof CapeTown","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejmech.2026.118841","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:35:45Z","timestamp":1775666145000},"page":"118841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structure\u2212Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors"],"prefix":"10.1016","volume":"312","author":[{"given":"Lutete Peguy","family":"Khonde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashied","family":"Peton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keabetswe","family":"Masike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Zindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fienberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Omollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Njoroge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Vallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tammaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schnappinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Ames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Biava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Poce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-1572","authenticated-orcid":false,"given":"Sandeep R.","family":"Ghorpade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chibale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118841_bib2","first-page":"2","volume":"ISBN 978-92-4-010153-1","year":"2024","journal-title":"Global Tuberculosis Report 2024"},{"key":"10.1016\/j.ejmech.2026.118841_bib3","series-title":"New Treatment for Drug-Resistant Tuberculosis","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118841_bib4","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: a turning point","volume":"130","author":"Vanino","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118841_bib5","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1021\/acs.jmedchem.2c00227","article-title":"Tuberculosis drug discovery: challenges and new Horizons","volume":"65","author":"Fernandes","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.drudis.2020.02.003","article-title":"The quest for the holy grail: new antitubercular chemical entities, targets and strategies","volume":"25","author":"Husz\u00e1r","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118841_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5099312","article-title":"Advances in key drug target identification and new drug development for tuberculosis","volume":"2022","author":"Mi","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2026.118841_bib8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acsinfecdis.6b00095","article-title":"Structure\u2013function profile of MmpL3, the essential mycolic acid transporter from Mycobacterium tuberculosis","volume":"2","author":"Belardinelli","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118841_bib9","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1128\/AAC.03229-14","article-title":"Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib10","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1128\/IAI.73.6.3492-3501.2005","article-title":"Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance","volume":"73","author":"Domenech","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2026.118841_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.chembiol.2012.03.006","article-title":"MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria","volume":"19","author":"Varela","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118841_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nchembio.794","article-title":"Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane","volume":"8","author":"Grzegorzewicz","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118841_bib13","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1073\/pnas.1700062114","article-title":"MmpL3 is the flippase for mycolic acids in mycobacteria","volume":"114","author":"Xu","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.118841_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21292\/2075-1230-2018-96-3-6-18","article-title":"Effectiveness and safety of A chemotherapy regimen including SQ109 in patients with multidrug-resistant pulmonary tuberculosis","volume":"96","author":"Borisov","year":"2018","journal-title":"Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2026.118841_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02399-16","article-title":"Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro","volume":"61","author":"Li","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib16","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.str.2021.06.013","article-title":"Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: an emergent therapeutic target","volume":"29","author":"Adams","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2026.118841_bib17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cell.2019.01.003","article-title":"Crystal structures of membrane transporter MmpL3, an Anti-TB drug target","volume":"176","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118841_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112390","article-title":"MmpL3 inhibitors as antituberculosis drugs","volume":"200","author":"Shao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib19","doi-asserted-by":"crossref","first-page":"13782","DOI":"10.1021\/acsomega.3c08401","article-title":"Novel inhibitors to MmpL3 transporter of Mycobacterium tuberculosis by structure-based high-throughput virtual screening and molecular dynamics simulations","volume":"9","author":"Choksi","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118841_bib20","doi-asserted-by":"crossref","first-page":"10534","DOI":"10.1021\/acs.jmedchem.2c00718","article-title":"Design, synthesis, and biological evaluation of Pyrrole-2-carboxamide derivatives as mycobacterial membrane protein large 3 inhibitors for treating drug-resistant tuberculosis","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109016","article-title":"Optimization of Pyrrole-2-carboxamide to develop a potent antituberculosis agent with improved physicochemical property and druggability","volume":"165","author":"Wu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107823","article-title":"Design, synthesis, biological evaluation study of spirocyclic POM analogues as novel MmpL3 anti-tubercular agent","volume":"153","author":"Mi Kim","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115351","article-title":"Structure-directed identification of Pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents","volume":"255","author":"Wen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.108464","article-title":"Design, synthesis, and biological evaluation of 1,2,4-Triazole derivatives as potent antitubercular agents","volume":"35","author":"Wen","year":"2024","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118841_bib25","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1021\/acsinfecdis.5c00394","article-title":"Common biological properties of Mycobacterium tuberculosis MmpL3 inhibitors","volume":"11","author":"Ames","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118841_bib26","doi-asserted-by":"crossref","first-page":"11327","DOI":"10.1021\/acs.jmedchem.8b01533","article-title":"Easy-to-synthesize spirocyclic compounds possess remarkable in vivo activity against Mycobacterium tuberculosis","volume":"61","author":"Guardia","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib27","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/AAC.42.11.3035","article-title":"Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains","volume":"42","author":"Deidda","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1128\/AAC.05270-11","article-title":"MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212","volume":"56","author":"La Rosa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib29","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1021\/acsmedchemlett.9b00204","article-title":"Novel pyrazole-containing compounds active against Mycobacterium tuberculosis","volume":"10","author":"Poce","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118841_bib30","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1021\/acs.jmedchem.0c01964","article-title":"Novel sigma 1 receptor antagonists as potential therapeutics for pain management","volume":"64","author":"Peng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib31","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J. Med. Chem."},{"issue":"2017","key":"10.1016\/j.ejmech.2026.118841_bib32","article-title":"Molecular connectivity predefines polypharmacology: aliphatic rings, chirality, and sp3 centers enhance target selectivity","volume":"8","author":"Monteleone","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118841_bib33","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cmdc.201700356","article-title":"Application of the pentafluorosulfanyl group as a bioisosteric replacement","volume":"12","author":"Sowaileh","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118841_bib34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/jac\/dkr472","article-title":"Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence","volume":"67","author":"Andreu","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib35","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1128\/AAC.00803-15","article-title":"Rapid, semiquantitative assay to discriminate among compounds with activity against replicating or nonreplicating Mycobacterium tuberculosis","volume":"59","author":"Gold","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00024-21","article-title":"Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits","volume":"65","author":"Egbelowo","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib37","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1021\/jm500131s","article-title":"Multitarget drug discovery for tuberculosis and other infectious diseases","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib38","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib39","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1128\/AAC.01178-16","article-title":"Bioluminescent reporters for rapid mechanism of action assessment in tuberculosis drug discovery","volume":"60","author":"Naran","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118841_bib40","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/JB.182.7.1802-1811.2000","article-title":"Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition","volume":"182","author":"Alland","year":"2000","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2026.118841_bib41","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1128\/JB.183.15.4459-4467.2001","article-title":"Identification of some DNA damage-inducible genes of mycobacterium tuberculosis: apparent lack of correlation with LexA binding","volume":"183","author":"Brooks","year":"2001","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2026.118841_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00985-20","article-title":"Multiple mutations in Mycobacterium tuberculosis MmpL3 increase resistance to MmpL3 inhibitors","volume":"5","author":"McNeil","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.ejmech.2026.118841_bib43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/acsinfecdis.0c00675","article-title":"Two-way regulation of MmpL3 expression identifies and validates inhibitors of MmpL3 function in Mycobacterium tuberculosis","volume":"7","author":"Grover","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118841_bib44","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1016\/j.jmb.2020.05.019","article-title":"Structural basis for the inhibition of mycobacterial MmpL3 by NITD-349 and SPIRO","volume":"432","author":"Yang","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118841_bib45","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/med.21476","article-title":"TOX-OER, C.H.K. researchers, collaborators, comprehensive review of cardiovascular toxicity of drugs and related agents","volume":"38","author":"Mlad\u011bnka","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118841_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1342761","article-title":"Cardiac arrhythmogenesis: roles of ion channels and their functional modification","volume":"15","author":"Lei","year":"2024","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejmech.2026.118841_bib47","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tips.2017.06.004","article-title":"Towards a structural view of drug binding to hERG K+ channels","volume":"38","author":"Vandenberg","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118841_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgae452","article-title":"The fully activated open state of KCNQ1 controls the cardiac \u201cFight-or-Flight\u201d response","volume":"3","author":"Hou","year":"2024","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.ejmech.2026.118841_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2014.00203","article-title":"Early identification of hERG liability in drug discovery programs by automated patch clamp","volume":"5","author":"Danker","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118841_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/acsinfecdis.6b00102","article-title":"The inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis","volume":"3","author":"Singh","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.118841_bib51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.ejmech.2026.118841_bib52","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: improving force field accuracy on challenging regimes of chemical space","volume":"17","author":"Lu","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.118841_bib53","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.ejmech.2026.118841_bib54","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118841_bib55","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/ci049780b","article-title":"Retrieval of crystallographically-derived molecular geometry information","volume":"44","author":"Bruno","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:31:07Z","timestamp":1777509067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":54,"alternative-id":["S0223523426002862"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118841","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure\u2212Activity relationship and optimization of drug-like properties of antituberculosis 3-(4,4-dimethyl-1,4-azasilinane)methylpyrazole MmpL3 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118841"}}